Finoriq insights
Yarrow Bioscience, Inc. (VYNE) SEC Filings & Filing Highlights
Yarrow Bioscience, Inc. also develops VYN202, a BD2-selective oral small molecule BET inhibitor. Review VYNE SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
- Company
- Yarrow Bioscience, Inc. (VYNE)
- Ticker
- VYNE
- Market Cap
- $929.4M
- Latest Price
- $27.84
- Industry
- Biotech & Pharma
Yarrow Bioscience, Inc. (VYNE) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Yarrow Bioscience, Inc. (VYNE).
| Event | Form | Date |
|---|---|---|
| 1 Bringing life into balance Yarrow Bioscience Overview May 20261 Bringing life into balance Yarrow Bioscience Overview May 2026 | 8-K7.01 | 2026-05-21 |
| VYNE THERAPEUTICS INCAs previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company... | 8-K3.01 | 2026-03-11 |
| Amendment to Merger AgreementOn January 30, 2026, VYNE Therapeutics Inc., a Delaware corporation (“VYNE”), Yarrow Merger Sub Corp., a Delaware corporation and a wholly-... | 8-K1.01 | 2026-01-30 |
| VYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementVYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement | 8-K7.01 | 2025-12-17 |
| To the extent required by this Item, the information included in Item 1.01 of this Current Repo...To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by ref... | 8-K5.02 | 2025-12-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.